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Four patients who had received tick bites while visiting 
forests in Mexico had skin lesions that met the case deﬁ  ni-
tion of erythema migrans, or borrelial lymphocytoma. Clini-
cal diagnosis was supported with histologic, serologic, and 
molecular tests. This study suggests that Borrelia burgdor-
feri infection is in Mexico.
L
yme disease is the most frequently reported vector-
borne infectious disease in the United States and Eu-
rope (1,2). Studies have suggested that Borrelia burgdorferi 
infection might be endemic to Mexico (3,4). We searched 
for histologic, immunologic, and molecular evidence of 
B. burgdorferi infection in patients with cutaneous mani-
festations suggestive of Lyme disease in Mexico.
The Study
From June 1999 to October 2000, 4 patients in Mexico 
City had clinical manifestations suggestive of Lyme disease 
(5,6). Two (36 and 54 years of age) had erythema migrans 
lesions, and 2 (9 and 34 years of age) had borrelial lym-
phocytoma lesions. Two reported having been bitten by a 
hard tick; the other 2, by a nonﬂ  ying insect. Bites occurred 
while camping in forests: 3 near Mexico City (National 
Park La Marquesa) and 1 in Quintana Roo, a southern state 
in Mexico. All patients lived in Mexico City and had never 
traveled outside Mexico.
Two patients were treated for acute skin lesions (con-
sistent with erythema migrans), malaise, and arthralgia. 
The skin lesion was an erythematous macula with regular, 
reddish edges and a pink center. One patient had a 5-cm le-
sion on the left forearm; the other had a 6-cm lesion on the 
left thigh. For the 2 other patients, a nodular erythematous 
cutaneous lesion (consistent with lymphocytoma), 0.5–2 
cm in diameter with regular edges, developed 2 months 
after the bite. One patient’s lesion was on the earlobe; the 
other’s, on the left cheek. 
Serum from each patient was tested for immunoglobu-
lin M (IgM) and IgG against B. burgdorferi sensu lato by 
using a commercial ELISA (cutoff optical density 0.200 
and indeterminate  0.200–0.400) (Enzygnost Borreliosis, 
Dade Behring, Marburg, Germany) (7). A Treponema pal-
lidum ELISA (Abbott Murex, Wiesbaden, Germany) was 
performed to rule out cross-reaction with T. pallidum infec-
tion. Serum samples positive for B. burgdorferi by ELISA 
were further tested by Western blot (WB) by using the 
Marxblot assay (MarDx Diagnostics, Carlsbad, CA, USA) 
and Centers for Disease Control and Prevention (CDC) 
criteria (5).
Serum samples from the 2 lymphocytoma patients 
were positive for B. burgdorferi by ELISA and WB (Fig-
ure 1, panel A; Table). For the 2 erythema migrans patients, 
serum samples taken 2 weeks after the tick bite were nega-
tive for B. burgdorferi IgM and IgG; but 2 months later, 1 
patient became seropositive, conﬁ  rmed by WB (Figure 1, 
panel B; Table).
Histologic examination of skin biopsy specimens from 
each erythema migrans lesion showed a mononuclear cell 
inﬁ  ltrate in the superﬁ  cial and deep dermis; inﬁ  ltrate in-
cluded lymphocytes and plasma cells around the perivas-
cular zones. Biopsy samples of lymphocytoma lesions 
showed dense nodular lymphocytic inﬁ  ltrates in the re-
ticular dermis with well-delineated lymphoid follicles, no 
atypical mitosis, B-lymphocytes (anti-CD20, DAKO, Car-
pentería, CA, USA) in the germinal center (Figure 2, panel 
A), T-lymphocytes (anti-CD45 RO+) in the follicular zone 
(Figure 2, panel B), and no CD3+ cells.
DNA was extracted from the biopsy samples (Repli-
g Mini Kit, QIAGEN, Valencia, CA, USA) and used for 
PCR ampliﬁ  cation of a fragment of ﬂ  a gene speciﬁ  c for B. 
burgdorferi sensu lato species as well as for a fragment of 
ospA gene, as described (8–10). DNA from a skin biopsy 
of a patient with systemic lupus erythematous was used as 
negative control, and DNA (10 pg/μL) from B. burgdorferi 
sensu stricto B31 served as positive control. All procedures 
from DNA extraction to ampliﬁ   cation were performed 
twice for each sample. Ampliﬁ  ed products were further 
tested by Southern blot (SB) hybridization with probes 
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Figure 1. Western Blot (WB) immunoglobulin G results from cutaneous 
cases. A) WB with serum from patient 1, showing erythema migrans. 
B) WB with serum from patient 4, showing lymphocytoma; a strong 
positive and a weak positive control were included. Borrelia burgdorferi and Lyme Disease, Mexico
speciﬁ  c for B. burgdorferi sensu stricto, B. garinii, and 
B. afzelii, as described (9). DNA from the 4 biopsy samples 
was positive for B. burgdorferi sensu lato ﬂ  a gene by PCR 
and conﬁ  rmed as B. burgdorferi sensu stricto by SB (on-
line Appendix Figure, available from www.cdc.gov/EID/
content/13/10/1556-appG.htm; Table). All DNA biopsy 
samples were negative by SB with the probes speciﬁ  c for 
B. garinii and B. afzelii.  We were able to amplify the OspA 
gene for only 1 case of erythema migrans, by using PCR 
and SB tests (data not shown).
The PCR products of the ﬂ  a gene from 3 patients and 
of the ospA gene from 1 patient were sequenced by using a 
commercial kit (GenomeLab DTCS-Quick Start Kit, Beck-
man Coulter, Inc., Fullerton, CA, USA) with the sequencer 
from Beckman Coulter, Inc., according to manufacturer’s 
instructions. We used the DNAMAN program (Lynnon 
Corporation, Vaudreuil-Dorion, Quebec, Canada) to align 
the sequences with the reported sequences of the B. burg-
dorferi sensu stricto B31 strain (online Appendix Figure). 
For the 2 erythema migrans cases, we found 3 base sub-
stitutions (online Appendix Figure, panel C), 1 of which 
was not conserved, leading to a change in amino acid (G 
for R in the 75 aa); these 2 sequences had 99% homology 
with the sequence of B. burgdorferi ﬂ  a gene of isolate B31 
(BLAST program) (11). For the lymphocytoma case, we 
found 2 base substitutions, the same as those of the ery-
thema migrans cases, including the nonconserved base sub-
stitution (online Appendix Figure, panel C).
Regarding the ospA gene in the erythema migrans 
case, the sequence showed 1 base substitution that was not 
conserved, leading to a change in the amino acid 5 (L for 
I). The sequence of this case had 99% homology with the 
plasmid Ip54 gene of B31strain sequence (11) (online Ap-
pendix Figure, panel D).
The 3 adult patients received doxycycline 200 mg/day 
for 3 weeks; the child received amoxicillin 50 mg/kg a day 
for 3 weeks. For all patients, lesions were gone at the end of 
the treatment and had not recurred 3 years later.
Conclusions
Erythema migrans is the diagnostic marker for Lyme 
disease associated with B. burgdorferi infection (5,6). His-
tologic data from our 2 erythema migrans cases agreed 
with data reported for other erythema migrans cases (5). 
Moreover, the 2 erythema migrans cases were positive for 
B. burgdorferi sensu stricto ﬂ  a gene and 1 for ospA gene; 
the 3 cases had a high degree of homology to the sequences 
of strain B31. In addition, 1 case met CDC criteria for sero-
positivity to B. burgdorferi infection (5).
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Figure 2. A case of lymphocytoma. A) Immunohistochemical 
image with anti-CD20 antibody showing a nodule with a dense B-
lymphocytes inﬁ  ltrate in the dermis (arrow); magniﬁ  cation ×100. B) 
Immunohistochemical image with anti-CD45 Ro antibody showing 
T-lymphocytes at the periphery of a nodule (arrow); magniﬁ  cation 
×250.
Table. Serologic IgG and molecular test results for patients with cutaneous lesions suggestive of Lyme borreliosis* 
Diagnosis ELISA OD  WB, molecular weight, kDa†  PCR for fla gene  SB‡
Erythema migrans  0.469 23,30,39,41,45,58  + Borrelia burgdorferi sensu stricto 
Erythema migrans  0.146 NT + B. burgdorferi sensu stricto 
Lymphocytoma 0.472 23,28,39,41,58,66  + B. burgdorferi sensu stricto 
Lymphocytoma 0.574 23,39,41,45,66,93 + B. burgdorferi sensu stricto 
*Ig, immunoglobulin; OD, optical density; WB, Western blot; SB, Southern blot; NT, not tested. 
†WB assay with B. burgdorferi sensu stricto antigen (Marxblot test), protein size of the bands recognized by the patient`s serum. 
‡SB  assay was done by using the probe specific for B. burgdorferi sensu stricto. DISPATCHES
Borrelial lymphocytoma is a rare clinical entity re-
ported mostly in Europe (12–14) and sporadically in the 
United States (15). In this study, histologic and immuno-
histochemical data from the 2 lymphocytoma cases agreed 
with data from previous cases.  These results were not spe-
ciﬁ  c enough to be considered diagnostic; however, germi-
nal centers are present in 80% of borrelial lymphocytoma 
cases (12). Serum samples from 2 patients were positive by 
WB, which fulﬁ  lls CDC criteria (5). In 1 case, ﬂ  a gene was 
ampliﬁ  ed and sequenced, showing high homology with the 
ﬂ  a gene from B. burgdorferi sensu stricto strain B31 (11). 
Few reports describe genotyping of B. burgdorferi spe-
cies in borrelial lymphocytoma. In Slovenia, B. afzelii and 
B. bissettii were identiﬁ  ed (13); in Germany, B. garinii was 
identiﬁ  ed (14). In our lymphocytoma patients, we identi-
ﬁ  ed B. burgdorferi sensu stricto. That the 2 borrelial lym-
phocytoma cases occurred in patients who had visited the 
same national park suggests that B. burgdorferi is endemic 
to that area.
This study documents B. burgdorferi infection in Mex-
ican patients. Relevant epidemiologic data are 1) cases oc-
curred after visiting forest areas, 2) patients reported having 
been bitten by a nonﬂ  ying insect, 3) cases occurred during 
the summer-fall season, 4) no patient reported having trav-
eled to another country, and 5) all skin lesions resolved 
after treatment with an antimicrobial drug. Our results sug-
gest that B. burgdorferi infection occurs in Mexico and that 
continuous surveillance for Lyme disease in Mexico should 
be mandatory.
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